This publication has been discontinued on June 28, 2011.
Abstract
Summary
GlobalData, the industry analysis specialist’s new report,
“Bipolar Disorder - Drug Pipeline Analysis and Market Forecasts to
2015” is an essential source of information and analysis on the global
bipolar disorder market. The report identifies the key trends shaping and
driving the dynamism in the global bipolar disorder market. The report also
provides insight on the prevalent competitive landscape and the emerging
players expected to bring significant shift in the market positioning of the
existing market leaders. Most importantly, the report provides valuable
insight on the pipeline products within the global bipolar disorder sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in house analysis by
GlobalData’s team of industry experts.
Scope
The scope of the report includes:
- Annualized global bipolar disorder
market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy,
Spain, Germany, France, and Japan.
- Pipeline analysis data providing a
split across different phases, mechanism of action being developed and
emerging trends. Key classes of mechanism of action include dopamine serotonin
receptor targettors, immunotherapy, enzyme inhibitors, serotonin receptor
modulators, acetylcholine inhibitors, muscarinic antagonists, combinational
therapy, ion channel modulators, dopamine agonist/antagonist and kappa opiod
agonists.
- Analysis of the current and future market competition in the
global bipolar disorder market. Each trend is independently researched to
provide qualitative analysis of what the implications on sectors are, and how
are companies responding to these trends.
- Insightful review of the
future market players, key industry drivers, restraints and challenges which
are likely to impact the bipolar disorder therapeutics market in the long run.
Key future market players covered are are Johnson & Johnson, Dainippon
Sumitomo, Lundebeck, Alexza and Repligen
- Key topics covered include
strategic competitor assessment, market characterization, unmet needs and
implications for future market associated with bipolar disorder.
Reasons to buy
The report will enhance your decision making capability in a more rapid and
time sensitive manner. It will allow you to:
- Develop and design your
in-licensing and out-licensing strategies through review of pipeline products
and technologies and by identifying companies with the most robust
pipeline.
- Develop business strategies by understanding the trends
shaping and driving the global bipolar disorder market.
- Drive revenues
by understanding key trends, innovative products and technologies, market
segments and companies likely to impact the global bipolar disorder market in
future.
- Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong
product portfolio and create effective counter-strategies to gain
competitive advantage.
- Organize your sales and marketing efforts by
identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global bipolar disorder market
landscape? - Identify, understand and capitalize.
Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2
Bipolar Disorder : Market Characterization
2.1 Overview
2.2 Bipolar
Disorder Market Size
2.3 Bipolar Disorder Market Forecast and CAGR
2.4
Drivers and Barriers for the Bipolar Disorder Market
2.4.1 Drivers for the
Bipolar Disorder Market
2.4.2 Barriers for the Bipolar Disorder Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Bipolar Disorder
Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor
Assessment
3.3 Product Profile for the Major Marketed Products in the
Bipolar Disorder Market
3.3.1 Abilify (Aripiprazole)
3.3.2 Symbyax
(Olazapine and fluoxetine Hcl)
3.3.3 Geodon (Ziprasidone
Hydrochloride)
3.3.4 Zyprexa (olazapine)
3.3.5 Equetro
(carbamazepine)
3.3.6 Seroquel (quetiapine fumarate)
3.3.7 Saphris
(SYNCREST, ORG-5222, asenapine)
3.4 Major Marketed Products Comparison in
the Bipolar Disorder Market
3.5 Key Takeaway
4 Bipolar Disorder
Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline
Assessment
4.2.1 Technology Trends Analytical Framework
4.3 Bipolar
Disorder Therapeutics -Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs Under Clinical Development
4.4.1
Bifeprunox mesylate
4.4.2 Invega (Paliperidone)
4.4.3 Lurasidone
(SM-13496)
4.4.4 Staccato Loxapine (AZ-004)
4.4.5 Nuvigil
(armodafinil)
4.4.6 RGH-188 (Cariprazine)
4.5 Bipolar Disorder
Therapeutics Market - Clinical Pipeline by Therapeutic Class
4.6
Bipolar Disorder Disease Pipeline - Pipeline by Clinical Phases of
Development
4.6.1 Bipolar Disorder Therapeutics - Phase III Clinical
Pipeline
4.6.2 Bipolar Disorder Therapeutics - Phase II Clinical
Pipeline
4.6.3 Bipolar Disorder Therapeutics - Phase I Clinical
Pipeline
4.6.4 Bipolar Disorder Therapeutics - Preclinical
Pipeline
4.7 Discontinued / Suspended Drugs for Bipolar Disorder
4.8
Key Takeaway
5 Global Bipolar Disorder Market: Implications for Future
Market Competition
6 Global Bipolar Disorder Market: Future Players in the
Bipolar Disorder Market
6.1 Introduction
6.2 Johnson & Johnson
6.2.1 Overview
6.2.2 CNS Portfolio
6.2.3 Bipolar Disorder
Portfolio
6.3 Dainippon Sumitomo Pharma
6.3.1 Overview
6.3.2 CNS
Portfolio
6.3.3 Bipolar Disorder Product Portfolio
6.4 Repligen
Corporation
6.4.1 Overview
6.4.2 CNS Portfolio
6.4.3 Bipolar
Disorder Product Portfolio
6.5 Lundbeck
6.5.1 Overview
6.5.2 CNS
Portfolio
6.5.3 Bipolar Disorder Product Portfolio
6.6 Alexza
Pharmaceuticals
6.6.1 Overview
6.6.2 CNS Portfolio
6.6.3 Bipolar
Disorder Product Portfolio
7 Global Bipolar Disorder Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1
Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary
Research
7.3.5 Expert Panel validation
7.4 Contact Us
7.5
Disclaimer
7.6 Sources
1.1 List of Tables
Table 1: Global
Bi-Polar Disorder and Schizophrenia Therapeutics Market, Revenue Forecasts,
2000-2008
Table 2: Global Bi-Polar Disorder and Schizophrenia Therapeutics
Market, Revenue Forecasts, 2009-2015
Table 3: Major Marketed Products
Comparison in the Bipolar Disorder Market, 2009
Table 4: Bipolar Disorder
Therapeutics - Most Promising Drugs Under Clinical Development, 2009
Table 5: Bipolar Disorder Therapeutics - Phase III Clinical Pipeline,
2009
Table 6: Bipolar Disorder Therapeutics - Phase II Clinical
Pipeline, 2009
Table 7: Bipolar Disorder Therapeutics - Phase I
Clinical Pipeline, 2009
Table 8: Bipolar Disorder Therapeutics -
Preclinical Clinical Pipeline, 2009
Table 9: List of Discontinued Drugs
for Bipolar Disorder, 2009
Table 10: Johnson & Johnson - CNS
Marketed Products, 2009
Table 11: Johnson & Johnson - CNS Pipeline
Products, 2009
Table 12: Dainippon Sumitomo-CNS Marketed Products,
2009
Table 13: Dainippon Sumitomo-CNS Pipeline Products, 2009
Table 14: Repligen Corporation - CNS Pipeline Products, 2009
Table
15: Lundbeck- CNS Marketed Products, 2009
Table 16: Lundbeck-
CNS Pipeline Products, 2009
Table 17: Alexza Pharmaceuticals - CNS
Pipeline Products, 2009
1.2 List of Figures
Figure 1: Global
Bi-Polar Disorder and Schizophrenia Therapeutics Market Forecast
,2000-2015
Figure 2: Opportunity and Unmet Need in the Bipolar Disorder
Market, 2009
Figure 3: Strategic Competitor Assessment of the Bipolar
Disorder Market, 2009
Figure 4: Technology Trends Analytic
Framework-Bipolar Disorder Market, 2009
Figure 5: Technology Trends
Analytic Framework - Description- Bipolar Disorder Market, 2009
Figure 6: Bipolar Disorder Therapeutics Market - Clinical Pipeline by
Mechanism of Action, 2009
Figure 7: Bipolar Disorder Therapeutics Market
- Clinical Pipeline by Mechanism of Action, 2009
Figure 8:
Implications For Future Market Competition in the Bipolar Disorder Market,
2009
Figure 9: Bipolar Disorder Therapeutics Market - Clinical
Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11:
GlobalData Market Forecasting Model
